Insider Selling: Billiontoone (NASDAQ:BLLN) SVP Sells $169,920.00 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $120.00, for a total value of $169,920.00. Following the transaction, the senior vice president directly owned 33,552 shares in the company, valued at approximately $4,026,240. This trade represents a 4.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Stock Performance

Shares of BLLN opened at $120.35 on Friday. The company’s 50 day moving average price is $96.21 and its 200 day moving average price is $87.92. Billiontoone, Inc. has a 52 week low of $61.96 and a 52 week high of $138.70. The company has a market capitalization of $5.53 billion and a PE ratio of 218.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92.

Billiontoone (NASDAQ:BLLN) last released its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The firm’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.39) EPS. Research analysts expect that Billiontoone, Inc. will post 0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

Several institutional investors have recently bought and sold shares of BLLN. Green Alpha Advisors LLC bought a new stake in shares of Billiontoone during the 4th quarter worth about $436,000. FNY Investment Advisers LLC acquired a new stake in Billiontoone in the 4th quarter worth approximately $497,000. Massachusetts Financial Services Co. MA bought a new stake in Billiontoone during the fourth quarter worth approximately $13,373,000. Baillie Gifford & Co. acquired a new position in Billiontoone during the fourth quarter valued at approximately $103,786,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Billiontoone during the fourth quarter valued at approximately $1,348,000.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BLLN. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Guggenheim started coverage on Billiontoone in a research note on Monday. They set a “buy” rating and a $125.00 price target for the company. Wall Street Zen upgraded Billiontoone from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. JPMorgan Chase & Co. increased their price objective on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, BTIG Research reduced their target price on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.